We were delighted to attend the latest edition of PCR London Valves as a Research Partner. 3 exciting days to learn, interact and network with the international Heart Teams and Industry Partners We are proud to be one of the only Contract Research Organizations present during the event. Many thanks to those who passed by our...
Excellent News for Colibri trial: the 1st recruited patient has been treated successfully on 15th September at the Clinique Pasteur Toulouse , by a team lead by Dr Tchétché! ...
Quality assistant The European Center for Cardiovascular Research (CERC) is a CRO specialized in the design and management of international clinical trials dedicated to cardiovascular diseases. Chaired by four interventional cardiologists, actors of clinical research for over 20 years, the CERC conducted clinical studies directly in line with the issues of cardiologists practicing in private or public hospitals. CERC is currently supporting thirty studies for industrial promotions but also manages more than 10 “investigators initiated trials” whose purpose is the treatment of conditions / comorbidities for which there is no satisfactory therapeutic strategy. CERC is an Entreprise à Mission. CERC is currently looking for a Quality assistant intern. Job description Performance of administrative tasks related to Quality assurance/ Quality Control activities Document management: document review, workflow follow up, distribution of documents (SOP, templates, …) and maintenance of CERC index Participation in the deployment and improvement of Quality Management System (QMS) tools Participation in the preparation of audits Contribution to staff support regarding to QMS and training process Skills Fluent English Good computer skills Knowledge of biotechnology or clinical research appreciated 12 reasons for joining us👉 https://www.cerc-europe.org/12-reasons/ The position is available immediately and is based in Massy, Essonne (91), France INTERESTED ? RESUME COVER...
The results of this huge trial were presented: On 08/28 at 2:00 p.m. on the Prime Time channel of the #ESCCongress, by Pr Marco Valgimigli, and simultaneously published in the New England Journal of Medecine, On 08/29 at 10:30 p.m 10:30 on Channel 5 : Pieter Smits, member of the CERC board and other PI of the study, discussed about antiplatelet therapy in high bleeding risk patients with and without oral anticoagulant therapy after coronary stenting. With a simultaneous publication in Circulation! With 111 study sites worldwide, CERC is very proud to be the main CRO in this huge game-changer study. About the trial > https://www.cerc-europe.org/master-dapt/ ...
CERC has adopted a new corporate form integrating the concept of a company with a mission (Entreprise à Mission). This new corporate form reaffirms CERC’s founding principle, namely, improving public health, whilst embodying our dedication to achieving societal and environmental goals. With the patients’ outcomes and quality of life as our ultimate purpose, our mission is to contribute to optimal healthcare via groundbreaking cardiovascular research. CERC is also committed to maintaining high standards of social and environmental corporate sustainability. Our strong commitment to pursuing this mission is now reflected in our new corporate rules and regulations. Our progress will undergo regular assessment under the guidance of an in-house monitoring committee. Finally, being able to join the quest for a third way in the corporate world is a great source of pride for CERC. ...
